EU Industry Wants End To Isolated National Measures On Coronavirus
Unilateral Supply-Chain Policies Could Lead To Damaging ‘Tit For Tat’
Executive Summary
A host of European pharmaceutical industry associations, including off-patent body Medicines for Europe, has urged EU trade ministers to push back against European and global restrictions on the movement of medicines and medical equipment that are hampering the international supply chain's response to the coronavirus pandemic.
You may also be interested in...
India Lifts Export Restrictions
India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.
EU Pharma Urges Rethink On Knee-Jerk Trade Policies In Global COVID-19 Fight
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
COVID-19: UK MHRA Says Non-Essential Inspections Will Be Office-Based
The UK’s Medicines and Healthcare products Regulatory Agency is replacing all non-essential on-site inspections with office-based assessments due to the coronavirus pandemic. The agency also plans to rely on information from international regulatory partners to maintain oversight.